NPM1 and acute myeloid leukemia: The interim phase 1a results from the KOMET-007 study regarding the application of Ziftomenib combined with VEN/AZA in R/R KMT2A or NPM1-mutated AML (NCT05735184) are shown in Table 2 [121].